Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques

Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses

(2015) Kristoffer Sahlholm et al.   PSYCHOPHARMACOLOGY

Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease

(2014) Katherine H O Deane et al.   BMJ Open

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease

(2013)   MOVEMENT DISORDERS

TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque

(2013) Tom H. Johnston et al.   NEUROPHARMACOLOGY

The dopaminergic stabilizer pridopidine decreases expression of l-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model

(2012) Henrik Ponten et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)

(2012) P. A. LeWitt et al.   NEUROLOGY

l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease

(2012) Philippe Huot et al.   NEUROPHARMACOLOGY

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

(2011) Justo Garcia de Yebenes et al.   LANCET NEUROLOGY

In vivo pharmacology of the dopaminergic stabilizer pridopidine

(2010) Henrik Ponten et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates

(2010) Tom H. Johnston et al.   MOVEMENT DISORDERS

Effects of (−)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization

(2008) Johan P. Rung et al.   JOURNAL OF NEURAL TRANSMISSION